Andrea Hayes-Jordan1, Richard Andrassy. 1. University of Texas MD Anderson Cancer Center, University of Texas Houston Health Sciences Center, Houston, TX 77030, USA. ahjordan@mdanderson.org
Abstract
PURPOSE OF REVIEW: Rhabdomyosarcoma is a rare childhood cancer that affects only approximately 300 children per year in the United States. The purpose of this review is to provide the reader a greater understanding of the complex diagnosis, assessment and treatment of rhabdomyosarcoma in children. RECENT FINDINGS: This review focuses on the new risk classification that is the foundation of all present rhabdomyosarcoma protocols developed by the Children's Oncology Group of the United States and Canada. The new risk classification of low, intermediate and high encompasses the staging and grouping categories that were previously utilized. SUMMARY: This review also provides a complete list of diagnostic tests and imaging required to identify rhabdomyosarcoma in any body site. Rapid diagnosis and recognition of this rare disorder will facilitate long-term survival. Rhabdomyosarcoma today has an overall survival of 70%, depending on the site, and in orbital and other sites survival is as high as 90%. The treatment approaches that have led to this doubling in survival over the last 25 years are reviewed. For a practitioner, this review can be used as a reference when a child with a suspicious mass is encountered.
PURPOSE OF REVIEW: Rhabdomyosarcoma is a rare childhood cancer that affects only approximately 300 children per year in the United States. The purpose of this review is to provide the reader a greater understanding of the complex diagnosis, assessment and treatment of rhabdomyosarcoma in children. RECENT FINDINGS: This review focuses on the new risk classification that is the foundation of all present rhabdomyosarcoma protocols developed by the Children's Oncology Group of the United States and Canada. The new risk classification of low, intermediate and high encompasses the staging and grouping categories that were previously utilized. SUMMARY: This review also provides a complete list of diagnostic tests and imaging required to identify rhabdomyosarcoma in any body site. Rapid diagnosis and recognition of this rare disorder will facilitate long-term survival. Rhabdomyosarcoma today has an overall survival of 70%, depending on the site, and in orbital and other sites survival is as high as 90%. The treatment approaches that have led to this doubling in survival over the last 25 years are reviewed. For a practitioner, this review can be used as a reference when a child with a suspicious mass is encountered.
Authors: Cathinka Boedicker; Michelle Hussong; Christina Grimm; Nadezda Dolgikh; Michael T Meister; Julius C Enßle; Marek Wanior; Stefan Knapp; Michal R Schweiger; Simone Fulda Journal: Oncogene Date: 2020-03-11 Impact factor: 9.867
Authors: Usha Avirneni-Vadlamudi; Kathleen A Galindo; Tiana R Endicott; Vera Paulson; Scott Cameron; Rene L Galindo Journal: J Clin Invest Date: 2011-12-19 Impact factor: 14.808
Authors: Joanna Radzikowska; Wojciech Kukwa; Andrzej Kukwa; Anna M Czarnecka; Maciej Kawecki; Fei Lian; Cezary Szczylik; Antoni Krzeski Journal: Oncol Lett Date: 2016-09-01 Impact factor: 2.967
Authors: David A Rodeberg; Julie A Stoner; Norbert Garcia-Henriquez; R Lor Randall; Sheri L Spunt; Carola A Arndt; Simon Kao; Charles N Paidas; Lynn Million; Douglas S Hawkins Journal: Cancer Date: 2010-12-14 Impact factor: 6.860